Juno Biomedical develops treatment for stroke patients to regain motor function

Juno Biomedical has announced the partnership with Promenade Software to further develop software for Juno Biomedical's CELLTech device, which uses 30 years of cell electrotaxis research to create a device that helps stroke patients regain motor function.

"It is very important to us that our device is not only safe and effective in returning motor function to those who are disabled after a stroke, but that it additionally takes into account patient functionality," said Trisha Pfluger, CEO. "This means integrating software that can monitor and optimize the patient's physical improvement while offering features that allow the patient and the patient's caregivers and family to be at the center of her therapy."

As the top cause of long-term disability in the U.S., strokes poise a significant risk to quality of life of patients. With no current FDA-approved treatment, the development of CELLTech could be a major stepping stone in recovering motor function for stroke patients. The software addition to CELLTech will adds several new features including feedback on patient monitoring in real time and a greater control over the dose of medication administered.

"This technology has the potential to save a tremendous amount of money by decreasing cost to the patient and insurance companies, while increasing top-line revenue for major stroke hospitals," said Allan Bernstein, MD, Medical Director of Sonoma West Research Institute and Clinical Advisor to Juno Biomedical. "Because of this, we have a clear path to market that not only fills an enormous need, but does so in a way that can reduce the current economic burden that has arisen from current limitations of stroke rehabilitation."